A recent study has revealed that a novel weight loss pill, known as orforglipron, is particularly effective for individuals with Type 2 diabetes. This appetite suppressing tablet has shown promising results in aiding weight loss and managing blood sugar levels. In a trial involving 1,500 participants, orforglipron was compared to the existing weight loss medication, semaglutide, which is available in injection form under the brand names Wegovy and Ozempic.
Developed by pharmaceutical company Eli Lilly, the same company behind the popular weight loss injection Mounjaro, orforglipron has garnered attention for its positive outcomes. While the injection form of Mounjaro demonstrated significant weight loss results, the pill form, including orforglipron, has shown a more modest yet notable weight reduction of 11% over a 17-month period.
The Lancet recently published the new findings, indicating that individuals taking orforglipron experienced a weight loss of 6% to 8% over a year, while those on semaglutide saw a weight reduction of 4% to 5%. These results have been lauded as a significant advancement in the treatment of Type 2 diabetes.
Weight loss injections have been praised for their impact on combatting obesity in severely overweight individuals, but there is a global shortage of these treatments. The National Health Service (NHS) in the UK is prioritizing individuals with severe obesity for these injections through specialized weight loss services due to limited capacity.
Approximately 2.2 million Britons are receiving weight loss injections through private prescriptions, emphasizing the need for broader access to appetite-suppressing medications, particularly in pill form, through the NHS.
The trial of orforglipron involved patients from various medical research centers and hospitals across different countries, including Argentina, China, Japan, Mexico, and the US. Experts, like Professor Naveed Sattar from Glasgow University, emphasize the importance of effective weight loss medications for individuals with Type 2 diabetes to address the underlying causes of the condition.
Unlike semaglutide, orforglipron offers the advantage of not requiring consumption on an empty stomach. However, the new pill has been associated with more side effects, such as nausea and stomach cramps, with some patients discontinuing its use due to severe reactions.
Lead researcher Julio Rosenstock, in partnership with Eli Lilly, views orforglipron as a potential breakthrough in treating individuals with Type 2 diabetes. Douglas Twenefour, clinical lead at Diabetes UK, highlights the effectiveness of GLP-1 medications in managing weight loss and Type 2 diabetes, underscoring the importance of offering a range of safe and efficient treatments to individuals with obesity and diabetes.
The introduction of an oral option like orforglipron, pending approval, could potentially reduce the risk of Type 2 diabetes and address the health implications associated with obesity, providing individuals with more treatment choices tailored to their preferences and clinical needs.